Achieve Life Sciences will join the Russell 2000® and Russell 3000® Indexes. This inclusion takes effect after the U.S. market opens on June 29, 2026. The move follows the annual reconstitution of the Russell U.S. Indexes. Membership provides a global benchmark for institutional investors and is expected to increase stock visibility and trading volume.
The company is currently developing cytisinicline as a treatment for nicotine dependence. The FDA recently issued a Complete Response Letter regarding the company's New Drug Application. This letter cited manufacturing issues at a third-party facility but raised no concerns regarding clinical efficacy or safety. Achieve plans to resubmit the application in the fourth quarter of 2026.